A Bibliometric Analysis of Research Progress on Pharmacovigilance and Cancer from 2002 to 2021

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Feb 10

PMID 36761953

Authors

Rina Sa

Yi Xu

Xinbo Pan

Yu Wang

Zhijian Lin

Xiaomeng Zhang

Bing Zhang

Affiliations

Soon will be listed here.

Abstract

The complexity of cancer itself and treatment makes pharmacovigilance critical in oncology. Despite rapid progress on pharmacovigilance and cancer research in the past two decades, there has been no bibliometric analysis in this field. Therefore, based on the Web of Science database, we used CiteSpace, VOS-viewer and R-bibliometrix to analyze and visualize publications, and described the development trend and research hot spots in this field. 502 publications were included. The development of pharmacovigilance and cancer research has continued to grow. The USA has the largest number of publications and citations, followed by France and UK. Vanderbilt University and Sorbonne University are the institutions that contribute the most papers, and 5 of the top 10 high-yield institutions are from France. Salem JE and Lebrun-Vignes B of Sorbonne University have published the most papers, and they have a strong cooperative relationship. Salem JE has the highest H index. has the largest number of publications in the field of pharmacovigilance and cancer, with a high impact factor (IF). In recent years, immune checkpoint inhibitors (ICIs) have been identified as a hot topic and will continue to be maintained. This paper can help researchers get familiar with the current situation and trend of pharmacovigilance and cancer research, and provide valuable reference for the selection of future research directions.

Citing Articles

Google Trends applications for COVID-19 pandemic: A bibliometric analysis.

Li H, Zhang N, Ma X, Wang Y, Yang F, Wang W Digit Health. 2025; 11:20552076241310055.

PMID: 39758260 PMC: 11696959. DOI: 10.1177/20552076241310055.

The reporting of disproportionality analysis in pharmacovigilance: spotlight on the READUS-PV guideline.

Fusaroli M, Salvo F, Khouri C, Raschi E Front Pharmacol. 2024; 15:1488725.

PMID: 39664518 PMC: 11632231. DOI: 10.3389/fphar.2024.1488725.

Mapping the Future: A Comprehensive Bibliometric Analysis of Circulating Tumor DNA in Colorectal Cancer.

Wang C J Multidiscip Healthc. 2024; 17:5473-5486.

PMID: 39600714 PMC: 11590644. DOI: 10.2147/JMDH.S493863.

Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis.

Xue Y, Zhang Y, Ding X, Wu X, Li B, Zhang Y Ann Nucl Med. 2024; 39(1):9-20.

PMID: 39499416 PMC: 11706862. DOI: 10.1007/s12149-024-01998-2.

Bibliometric and Visualization Analysis of Research Hotspots and Frontiers in Endoscopic Lumbar Discectomy.

Zhong Y, Wang J, Liang Z, Han T, Lu H, Hou Z J Pain Res. 2024; 17:2165-2190.

PMID: 38910593 PMC: 11193472. DOI: 10.2147/JPR.S450586.

References

Cutroneo P, Isgro V, Ientile V, Santarpia M, Ferlazzo G, Fontana A . Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. Br J Clin Pharmacol. 2020; 87(2):527-541. DOI: 10.1111/bcp.14413. View

Dorks M, Jobski K, Herget-Rosenthal S, Hoffmann F, Douros A . Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis. Pharmacol Res Perspect. 2021; 9(1):e00707. PMC: 7796803. DOI: 10.1002/prp2.707. View

Hauben M, Hung E, Wood J, Soitkar A, Reshef D . The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017; 8(5):145-156. PMC: 5444595. DOI: 10.1177/2042098616685010. View

Huang L, Shi X, Zhang N, Gao Y, Bai Q, Liu L . Bibliometric analysis of trends and issues in traditional medicine for stroke research: 2004-2018. BMC Complement Med Ther. 2020; 20(1):39. PMC: 7076850. DOI: 10.1186/s12906-020-2832-x. View

Manfredi S . The "old" cytotoxic drugs, the basis of anti-cancer treatments. Therapie. 2021; 77(2):251-255. DOI: 10.1016/j.therap.2021.11.006. View

Alexandre J, Salem J, Moslehi J, Sassier M, Ropert C, Cautela J . Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database. Eur Heart J Cardiovasc Pharmacother. 2020; 7(4):312-320. DOI: 10.1093/ehjcvp/pvaa037. View

Suresh K, Naidoo J, Lin C, Danoff S . Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest. 2018; 154(6):1416-1423. PMC: 6335259. DOI: 10.1016/j.chest.2018.08.1048. View

He X, Yu J, Shi H . Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. Front Pharmacol. 2021; 12:797852. PMC: 8652050. DOI: 10.3389/fphar.2021.797852. View

Casak S, Lemery S, Chung J, Fuchs C, Schrieber S, Chow E . FDA's Approval of the First Biosimilar to Bevacizumab. Clin Cancer Res. 2018; 24(18):4365-4370. DOI: 10.1158/1078-0432.CCR-18-0566. View

10.

Harvey R . Science of Biosimilars. J Oncol Pract. 2017; 13(9_suppl):17s-23s. DOI: 10.1200/JOP.2017.026062. View

11.

Johnson D, Nebhan C, Moslehi J, Balko J . Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022; 19(4):254-267. PMC: 8790946. DOI: 10.1038/s41571-022-00600-w. View

12.

Huang L, Xu G, He J, Tian H, Zhou Z, Huang F . Bibliometric Analysis of Functional Magnetic Resonance Imaging Studies on Acupuncture Analgesia Over the Past 20 Years. J Pain Res. 2021; 14:3773-3789. PMC: 8670890. DOI: 10.2147/JPR.S340961. View

13.

Ruggiero R, Fraenza F, Scavone C, Mauro G, Piscitelli R, Mascolo A . Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. Front Pharmacol. 2020; 11:830. PMC: 7295943. DOI: 10.3389/fphar.2020.00830. View

14.

Tuccori M, Montagnani S, Capogrosso-Sansone A, Mantarro S, Antonioli L, Fornai M . Adverse reactions to oncologic drugs: spontaneous reporting and signal detection. Expert Rev Clin Pharmacol. 2014; 8(1):61-75. DOI: 10.1586/17512433.2015.974555. View

15.

van Grootheest A, de Jong-van den Berg L . The role of hospital and community pharmacists in pharmacovigilance. Res Social Adm Pharm. 2006; 1(1):126-33. DOI: 10.1016/j.sapharm.2004.12.009. View

16.

Doroshow D, Bhalla S, Beasley M, Sholl L, Kerr K, Gnjatic S . PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021; 18(6):345-362. DOI: 10.1038/s41571-021-00473-5. View

17.

Ouyang W, Xie W, Xin Z, He H, Wen T, Peng X . Evolutionary Overview of Consumer Health Informatics: Bibliometric Study on the Web of Science from 1999 to 2019. J Med Internet Res. 2021; 23(9):e21974. PMC: 8461533. DOI: 10.2196/21974. View

18.

Gul A, Stewart T, Mantia C, Shah N, Stern Gatof E, Long Y . Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors. J Clin Oncol. 2020; 38(27):3088-3094. PMC: 7499610. DOI: 10.1200/JCO.19.03315. View

19.

Barasch A, Peterson D . Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003; 39(2):91-100. DOI: 10.1016/s1368-8375(02)00033-7. View

20.

Rugo H, Barve A, Waller C, Hernandez-Bronchud M, Herson J, Yuan J . Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA. 2016; 317(1):37-47. DOI: 10.1001/jama.2016.18305. View